Nevirapine

Drug Profile

Nevirapine

Alternative Names: BI-RG-587; BIRG 0587; Extended release nevirapine; Nevirapine ER; Nevirapine XR; NSC 641530; Viramune; Viramune Extended Release; Viramune XR

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class 3-ring heterocyclic compounds; Antiretrovirals; Azepines; Cyclopropanes; Pyridines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 23 May 2012 Generic nevirapine equivalent available in the US for HIV-1 infections
  • 07 Feb 2012 Boehringer Ingelheim completes a phase III trial of extended-release nevirapine in HIV-1 infections (treatment-naive) in US, Argentina, Australia, Belgium, Botswana, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Russia, South Africa, Spain, Switzerland & UK (NCT00561925)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top